Pharmacokinetics

Red Light Holland Receives Patent Pending Status For 'Find Your Dose' Customization of Microdosing Kits Based on Biometric and Movement Data

Wednesday, May 5, 2021 - 1:20pm

Utilizing this data to help people find the psilocybin microdose that works best for them can potentially be a breakthrough in personalization of wellness applications," said Sarah Hashkes, Red Light Holland\'s Chief Technology and Innovation Officer.

Key Points: 
  • Utilizing this data to help people find the psilocybin microdose that works best for them can potentially be a breakthrough in personalization of wellness applications," said Sarah Hashkes, Red Light Holland\'s Chief Technology and Innovation Officer.
  • "\n"Working with natural substances and combining them with cutting edge innovation and proprietary technology to hopefully help people as opposed to limiting people, is now the way of the future," added Todd Shapiro, CEO and Director of Red Light Holland.
  • Learning about these potential benefits and being a part of developing precise dosages for the betterment of consumers is now a more realistic goal for Red Light Holland.
  • (See, e.g., Anderson et al., Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.

Gastroretentive Drug Delivery Systems Market Size Worth $19.7 Billion By 2028: Grand View Research, Inc.

Tuesday, May 4, 2021 - 9:35am

b'SAN FRANCISCO, May 4, 2021 /PRNewswire/ --The global gastroretentive drug delivery systems market size is estimated to reach USD 19.7 billion by 2028, registering a CAGR of 6.4%, according to a new report by Grand View Research, Inc. Gastroretentive Drug Delivery Systems (DDSs) offer possible advantages for the drug with poor bioavailability, as their absorption is restricted to the upper Gastrointestinal Tract (GIT) and can be delivered proficiently.

Key Points: 
  • b'SAN FRANCISCO, May 4, 2021 /PRNewswire/ --The global gastroretentive drug delivery systems market size is estimated to reach USD 19.7 billion by 2028, registering a CAGR of 6.4%, according to a new report by Grand View Research, Inc. Gastroretentive Drug Delivery Systems (DDSs) offer possible advantages for the drug with poor bioavailability, as their absorption is restricted to the upper Gastrointestinal Tract (GIT) and can be delivered proficiently.
  • The controlled and systematic DDS minimizes the chances of medicine overexposure at the diseased site.
  • Hence, various advantages associated with gastroretentive DDSs are expected to foster the overall market progression.\nThe DDS sustains the release of drugs and avails local therapy in the small intestine and stomach.
  • Hence, the above-mentioned factors are predicted to augment market expansion.\nGrand View Research has segmented the global gastroretentive drug delivery systems market on the basis of type, dosage form, distribution channel, and region:\n'

Agilex Biolabs Congratulates Bionomics Limited on BNC210 PK Results

Friday, April 30, 2021 - 5:00am

b'ADELAIDE, AUS, Apr 30, 2021 - (ACN Newswire) - Agilex Biolabs, Australia\'s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today congratulated client Bionomics Limited (Bionomics) on its positive pharmacokinetic (PK) results from a 7-day dosing study in healthy volunteers using the newly developed solid dose oral tablet formulation of BNC210.\nLiz Doolin, Bionomics\' Vice President Clinical Development commented that "We greatly value our long-standing partnership with Agilex Biolabs who continue to be a partner of choice for Bionomics and have supported the development of BNC210 from the beginning.

Key Points: 
  • b'ADELAIDE, AUS, Apr 30, 2021 - (ACN Newswire) - Agilex Biolabs, Australia\'s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today congratulated client Bionomics Limited (Bionomics) on its positive pharmacokinetic (PK) results from a 7-day dosing study in healthy volunteers using the newly developed solid dose oral tablet formulation of BNC210.\nLiz Doolin, Bionomics\' Vice President Clinical Development commented that "We greatly value our long-standing partnership with Agilex Biolabs who continue to be a partner of choice for Bionomics and have supported the development of BNC210 from the beginning.
  • "\nBionomics (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5), is a global, clinical stage biopharmaceutical company.
  • Agilex Biolabs has been working closely with Bionomics for several years, supporting the PK regulated Bioanalysis of BNC210 and is privileged to be a part of this potential new treatment for anxiety and stressor-related disorders.
  • Australian clinical trials have remained open for business and Agilex Biolabs is a designated essential service so clients can be assured of study continuity.

Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights

Thursday, April 29, 2021 - 9:15pm

Pharvaris continues to expect study initiation in 2021.\nPhase 1 pharmacokinetics study of PHVS719 to begin by the end of 2021.

Key Points: 
  • Pharvaris continues to expect study initiation in 2021.\nPhase 1 pharmacokinetics study of PHVS719 to begin by the end of 2021.
  • In January 2021, Pharvaris announced clinical data from the Company\xe2\x80\x99s Phase 1 multiple-ascending dose study, demonstrating the oral bioavailability of PHA121.
  • PHA121 was well tolerated at all doses studied, with approximately dose-proportional exposure.\nPresentations of clinical data of PHA121 at medical conferences.
  • Berndt Modig, co-founder and chief executive officer of Pharvaris, and Morgan Conn, Ph.D., chief business officer of Pharvaris, will participate in a fireside chat via online video on Wednesday, May 12.

Agilex Biolabs and B2S Life Sciences on Immunoassay Bioanalysis for Clinical Trials

Wednesday, April 28, 2021 - 8:00pm

Sales, Agilex Biolabs\' Director of Immunoassay, Ronald R. Bowsher PhD, Partner and Chief Scientific Officer at B2S Life Sciences, and Amy Rosen, Associate Director of Statistics at B2S.\nThe panel shared insights from many years working in immunoassay bioanalysis for clinical trials.

Key Points: 
  • Sales, Agilex Biolabs\' Director of Immunoassay, Ronald R. Bowsher PhD, Partner and Chief Scientific Officer at B2S Life Sciences, and Amy Rosen, Associate Director of Statistics at B2S.\nThe panel shared insights from many years working in immunoassay bioanalysis for clinical trials.
  • Ronald R. Bowsher said B2S has been working with Agilex Biolabs for more than four years, "Our relationship has evolved very well, and we understand each other\'s needs.
  • And despite the geographic differences, I think we\'ve had a very productive collaboration serving Agilex Biolabs\' customers," he said.\nDr Kurt J.
  • We offer services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilising the two platforms of LC-MS/MS and Immunoassay.\n'

Surface Oncology to Present Clinical Updates for SRF388 and SRF617

Wednesday, April 28, 2021 - 9:05pm

In conjunction, Surface will host a webcast on Friday, June 4, 2021 at 8:00 a.m. to review the SRF388 clinical data as well as to provide a clinical update from the company\xe2\x80\x99s ongoing SRF617 Phase 1 study.\n\xe2\x80\x9cWe\xe2\x80\x99re excited to share clinical data on our lead therapeutic candidates, both of which are first-in-class,\xe2\x80\x9d said Alison O\xe2\x80\x99Neill, M.D., chief medical officer at Surface Oncology.

Key Points: 
  • In conjunction, Surface will host a webcast on Friday, June 4, 2021 at 8:00 a.m. to review the SRF388 clinical data as well as to provide a clinical update from the company\xe2\x80\x99s ongoing SRF617 Phase 1 study.\n\xe2\x80\x9cWe\xe2\x80\x99re excited to share clinical data on our lead therapeutic candidates, both of which are first-in-class,\xe2\x80\x9d said Alison O\xe2\x80\x99Neill, M.D., chief medical officer at Surface Oncology.
  • The first portion of the study will establish the preliminary safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of SRF388 as a monotherapy and identify a dose suitable for expansion studies.
  • Furthermore, Surface Oncology has identified a potential biomarker associated with IL-27 that may be useful in helping to identify patients most likely to respond to SRF388.
  • The monotherapy tumor biopsy expansion portion of the study will further evaluate the safety and intratumoral pharmacodynamics of SRF617 as a monotherapy.

Trillium Therapeutics Provides Data Update, Announces Phase 1b/2 Program Priorities Across Hematologic Malignancies and Solid Tumors, and Reports Governance Changes

Wednesday, April 28, 2021 - 12:00pm

In parallel, we are continuing to evaluate less frequent dosing regimens than our current weekly dosing.

Key Points: 
  • In parallel, we are continuing to evaluate less frequent dosing regimens than our current weekly dosing.
  • \xe2\x80\x9cBob has played a pivotal role in transitioning the CEO leadership in 2019, and positioning the company for our subsequent transformation program in 2020.
  • Trillium would not be where it is today without Bob\xe2\x80\x99s leadership, hands-on contributions and personal sacrifices.
  • Pharmacokinetic data demonstrated dose-proportional increases in drug exposure between 8 and 18 mg/kg, and support evaluating less frequent dosing.

Simulations Plus Releases ADMET Predictor® (X.2)

Tuesday, April 27, 2021 - 1:30pm

b'Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has released version 10.2 of its flagship machine learning modeling platform, ADMET Predictor\xc2\xae .

Key Points: 
  • b'Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has released version 10.2 of its flagship machine learning modeling platform, ADMET Predictor\xc2\xae .
  • The new release will be marketed as APX.2.\nKey enhancements in APX.2 include:\nDr.
  • David Miller , vice president of ADMET cheminformatics, said: \xe2\x80\x9cAPX.2 enhances the industry-leading discovery PBPK modeling capabilities within ADMET Predictor and cements the program as the premier environment for ADMET property prediction modeling.
  • Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide.

Worldwide Therapeutic Drug Monitoring Industry to 2030 - Unmet Needs and Strategies for the Development of Markets

Thursday, April 22, 2021 - 10:45pm

b'DUBLIN, April 22, 2021 /PRNewswire/ -- The "Therapeutic Drug Monitoring - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nThis report deals with therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to individually adjust the dose of drugs for improving outcome.

Key Points: 
  • b'DUBLIN, April 22, 2021 /PRNewswire/ -- The "Therapeutic Drug Monitoring - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nThis report deals with therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to individually adjust the dose of drugs for improving outcome.
  • TDM is viewed as a component of personalized medicine that interacts with several other disciplines including pharmacokinetics and pharmacogenetics.
  • Unmet needs and strategies for the development of markets for TDM are discussed.
  • The report contains profiles of 35 companies involved in developing tests and equipment for drug monitoring along with their collaborations.

CURE Pharmaceutical Announces Successful Results From Initial Clinical Trials for Erectile Dysfunction Product CUREfilm Blue™

Wednesday, April 21, 2021 - 1:15pm

b'CURE Pharmaceutical Holding Corp. (\xe2\x80\x9cCURE\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) (OTC: CURR), a technology focused, vertically integrated specialty pharmaceutical company, announced today successful results from its initial Pharmacokinetics (PK)/bioequivalence studies.

Key Points: 
  • b'CURE Pharmaceutical Holding Corp. (\xe2\x80\x9cCURE\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) (OTC: CURR), a technology focused, vertically integrated specialty pharmaceutical company, announced today successful results from its initial Pharmacokinetics (PK)/bioequivalence studies.
  • CURE will now advance its clinical program with the objective of U.S. Food and Drug Administration (FDA) approval.\nCUREfilm Blue\xe2\x84\xa2 utilizes the Company\xe2\x80\x99s patented and proprietary fast-dissolving drug delivery platform, known as CUREfilm\xe2\x84\xa2, to deliver the active pharmaceutical ingredient (API) sildenafil citrate.
  • The forward-looking statements in this press release reflect CURE\xe2\x80\x99s judgment as of the date of this press release.
  • CURE disclaims any intent or obligation to update these forward-looking statements.